Pharmaniaga Bhd (PHARMA)

Pharmaniaga Bhd (PHARMA / 7081) — Rising From PN17

Pharmaniaga Bhd is a remarkable recovery story. Malaysia's largest pharmaceutical company by government distribution fell into PN17 status in February 2023 — the result of a RM552.3 million provision for slow-moving COVID-19 vaccine inventories. Three years later, on March 17, 2026, Pharmaniaga successfully exited PN17 after completing a challenging regularisation plan.

What makes this story compelling is not just the PN17 exit itself — but what Pharmaniaga is building afterward. The company is transforming from a low-margin distribution player into a high-margin pharmaceutical manufacturer, with human insulin and vaccines as its key growth catalysts.

Core Business Segments

• Government Concession (MOH) — A 7-year concession contract (renewed 2023, valid until ~2030) to supply pharmaceuticals and medical products to government hospitals nationwide. This is the backbone of Pharmaniaga's revenue, contributing ~70-80% of total revenue. Gross margin in this segment is approximately 6-10%.
• Manufacturing (Pharmaniaga Lifescience) — A new biopharma plant in Puchong began full operations in 2026. Pharmaniaga is now MALAYSIA'S FIRST DOMESTIC HUMAN INSULIN PRODUCER after winning a RM281.67 million contract from the Ministry of Health (March 2026, 3-year tenure). Vaccine revenue is projected at approximately RM300 million annually.
• Logistics & Distribution — Warehouse management and delivery to government hospitals. Supports the concession segment.
• Consumer/Trading — Smaller segment including OTC products and wholesale healthcare products.

Shariah Status

✅ Shariah Compliant — Pharmaniaga is confirmed as a Shariah-compliant stock, suitable for investors prioritising halal investments.

Major Shareholders

• Boustead Holdings Bhd: 35.2% (GLC linked to LTAT)
• LTAT (Armed Forces Fund Board): 8.7% direct
• LTAT + Boustead combined = 43.9% — majority controlled by Malaysia's armed forces pension fund

Following the rights issue (RM353.5 million raised) and private placement (RM223.7 million from 19 new investors), Pharmaniaga's total share count is now 6.55 billion units — a significant dilution from its pre-exercise base.

This section is being refreshed with the latest figures. Please check back soon.

This section is being refreshed with the latest figures. Please check back soon.